Overview

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Weill Medical College of Cornell University
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins